Sg Americas Securities, LLC Relmada Therapeutics, Inc. Transaction History

Sg Americas Securities, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$3.1 - $6.8 $35,092 - $76,976	11,320 New	11,320 $53,000
Q3 2022 Oct 31, 2022	BUY	$18.3 - $37.02 $369,989 - $748,470	20,218 Added 97.8%	40,890 $1.51 Million
Q2 2022 Jul 29, 2022	SELL	$16.5 - $30.34 $1.39 Million - $2.55 Million	-84,145 Reduced 80.28%	20,672 $393,000
Q1 2022 Apr 29, 2022	SELL	$16.72 - $26.99 $829,863 - $1.34 Million	-49,633 Reduced 32.14%	104,817 $2.83 Million
Q4 2021 Feb 07, 2022	BUY	$16.93 - $26.82 $2.5 Million - $3.96 Million	147,653 Added 2172.33%	154,450 $3.48 Million
Q3 2021 Nov 01, 2021	BUY	$21.86 - $34.77 $148,582 - $236,331	6,797 New	6,797 $178,000
Q1 2021 May 13, 2021	SELL	$31.52 - $39.28 $536,911 - $669,095	-17,034 Closed	0 $0
Q4 2020 Feb 04, 2021	SELL	$29.88 - $39.8 $1.34 Million - $1.79 Million	-44,919 Reduced 72.5%	17,034 $546,000
Q3 2020 Nov 09, 2020	BUY	$34.42 - $43.78 $1.87 Million - $2.38 Million	54,281 Added 707.52%	61,953 $2.33 Million
Q2 2020 Jul 20, 2020	BUY	$31.59 - $49.98 $242,358 - $383,446	7,672 New	7,672 $343,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $79M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.